Skip to content
The biotechnology industry is one of the riskiest and the most challenging—but it is also one of the few that makes the difference between […]
2022 was a challenging year for biotechnology. What’s in store for 2023? Read More »
In their efforts to harness a new way “to turn cancer cells into potent anticancer agents,” researchers developed a new stem cell therapy to
This vaccine can simultaneously kill and prevent brain cancer Read More »
Despite the fact the United States is still dealing with the COVID-19 pandemic, the Center for Drug Evaluation and Research (CDER) of the U.S.
FDA approved 37 ‘novel’ drugs in 2022, says new analysis Read More »
According to a new study from the American Cancer Society Cancer published Thursday, cancer deaths in the United States have decreased by 33% over
Cancer deaths down 33% in three decades, new study shows Read More »
As researchers raced to identify new COVID-19 subvariants, worldwide capacity for genomic sequencing increased, enabling the application of the process for other public health
Boosted by COVID, genomic sequencing gains traction globally Read More »
The 41st J.P. Morgan Healthcare Conference is taking place in San Francisco this week, and the Biotechnology Innovation Organization (BIO) has been helping attendees
J.P. Morgan health event brings big deals; BIO platform boosts partnering Read More »
In 2022 drug manufacturers actually charged less for their products and patients paid slightly more than the previous year—but the cost of prescription medicines
While net drug prices drop, patients pay more thanks to health plans and PBMs Read More »
Biopharmaceutical company Ocugen announced its COVID-19 vaccine candidate Covaxin, developed by Bharat Biotech, showed positive results in the U.S. trial. Ocugen, a Biotechnology Innovation
Ocugen’s vaccine candidate Covaxin met both co-primary endpoints in study Read More »
One positive outcome of the COVID-19 pandemic is the advancement of mRNA technology, which is on track to help us create the next wave
Is mRNA technology the new standard in vaccine-making? Read More »
The U.S. Food and Drug Administration (FDA) on Friday granted accelerated approval for the Alzheimer’s drug LEQEMBI (lecanemab-irmb). The drug is developed by two biotech
FDA grants accelerated approval for Eisai’s new Alzheimer’s drug Read More »
